Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial

Abstract

Our data failed to show the non-inferiority of 1 mg of GRN to 3 mg of GRN administered as a single dose. However, the rate of complete protection from nausea and vomiting was similar in the two groups. Given the recommended dosage in the guidelines and the economic need for reduction of medical care expenses in Japan, prophylactic administration of GRN at 1 mg may be an appropriate, alternative treatment for acute CINV in cancer patients.

Cost-Effectiveness Analysis of Granisetron-Based versus Standard Antiemetic Regimens in Low-Emetogenic Chemotherapy: A Hospital-based Perspective from Malaysia

“…It has been given as a single dose of 3mg in our hospital irrespective of patients' body weight. Studies have been demonstrating the similar response rates for doses of 1mg and 3mg Yonemura et al, 2009). Using 1mg granisetron (Kytril ® ) might have reduced the ICER by approximately two-third.…”

Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial

“…A small non-inferiority study comparing 3 and 1 mg of granisetron was recently conducted in Japan [26]. However, it did not statistically demonstrate the noninferiority of 1 mg granisetron to 3 mg.…”

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review

“…In highly emetogenic chemotherapy, the higher rates of emesis control are achieved with 3-drug regimens combining 5-HT 3 antagonists, dexamethasone, and aprepitant (83% to 93% in acute emesis and 79% to 76% in delayed emesis) 6,27,28,64,68–70. The clinical trials that included specifically granisetron combined with dexamethasone reported a rate of complete emesis control in 60% and 86% of patients, higher than the 70% with intravenous granisetron,61 and 60% to 86% with oral granisetron 62–64. A recent phase III clinical trial comparing palonosetron plus dexamethasone with intravenous granisetron plus dexamethasone in highly emetogenic chemotherapy reported a 73.3% complete response with granisetron plus dexamethasone 42…”